• 1
    Ahles TA,Saykin AJ,Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 2
    Brezden CB,Phillips KA,Abdolell M,Bunston T,Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 26952701.
  • 3
    Castellon SA,Ganz PA,Bower JE,Petersen L,Abraham L,Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26: 955969.
  • 4
    Schagen SB,van Dam FS,Muller MJ,Boogerd W,Lindeboom J,Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640650.
  • 5
    van Dam FS,Schagen SB,Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210218.
  • 6
    Wieneke MH,Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995; 4: 6166.
  • 7
    Bender CM,Sereika SM,Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-oncology. 2006; 15: 422430.
  • 8
    Stewart A,Collins B,Mackenzie J,Tomiak E,Verma S,Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-oncology. 2008; 17: 122130.
  • 9
    Wefel JS,Lenzi R,Theriault RL,Davis RN,Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 22922299.
  • 10
    Schagen SB,Muller MJ,Boogerd W,Mellenbergh GJ,van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006; 98: 17421745.
  • 11
    Shilling V,Jenkins V,Trapala IS. The (mis)classification of chemo-fog—methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006; 95: 125129.
  • 12
    Schagen SB,Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol. 2007; 8: 852853.
  • 13
    Jenkins V,Shilling V,Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828834.
  • 14
    Wefel JS,Lenzi R,Theriault R,Buzdar AU,Cruickshank S,Meyers CA. “Chemobrain” in breast carcinoma? A prologue. Cancer. 2004; 101: 466475.
  • 15
    Ahles TA,Saykin AJ,McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2007; 110: 143152.
  • 16
    Hermelink K,Untch M,Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007; 109: 19051913.
  • 17
    Vardy J,Rourke S,Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007; 25: 24552463.
  • 18
    Vardy J,Wefel JS,Ahles T,Tannock IF,Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008; 19: 623629.
  • 19
    Hurria A,Somlo G,Ahles T. Renaming “chemobrain.” Cancer Invest. 2007; 25: 373377.
  • 20
    Jenkins V,Atkins L,Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer. 2007; 43: 13421347.
  • 21
    Gibbs RB. Preclinical data relating to estrogen's effects on cognitive performance. In: Rasgon NL, ed. The Effects of Estrogen on Brain Function. Baltimore, Md: Johns Hopkins University Press; 2006: 945.
  • 22
    Yaffe K,Sawaya G,Lieberburg I,Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998; 279: 688695.
  • 23
    Brinton RD,Zhao L. Preclinical efforts to develop effective neuro-SERMs for the brain. In: Rasgon NL, ed. The Effects of Estrogen on Brain Function. Baltimore, Md: Johns Hopkins University Press; 2006: 116143.
  • 24
    Geerlings MI,Launer LJ,de Jong FH, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol. 2003; 53: 607615.
  • 25
    Shumaker SA,Legault C,Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 26512662.
  • 26
    Shumaker SA,Legault C,Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291: 29472958.
  • 27
    Rapp SR,Espeland MA,Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 26632672.
  • 28
    Hogervorst E,Williams J,Budge M,Riedel W,Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000; 101: 485512.
  • 29
    LeBlanc ES,Janowsky J,Chan BK,Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001; 285: 14891499.
  • 30
    Ernst T,Chang L,Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. JNatl Cancer Inst. 2002; 94: 592597.
  • 31
    Eberling JL,Wu C,Tong-Turnbeaugh R,Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004; 21: 364371.
  • 32
    Paganini-Hill A,Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000; 64: 165176.
  • 33
    Fan HG,Houede-Tchen N,Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005; 23: 80258032.
  • 34
    Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol. 2007; 106: 168172.
  • 35
    Jenkins V,Shilling V,Fallowfield L,Howell A,Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-oncology. 2004; 13: 6166.
  • 36
    Bender CM,Sereika SM,Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007; 14: 995998.
  • 37
    Harting C,Markowitsch HJ,Neufeld H,Calabrese P,Deisinger K,Kessler J.WMS-R. Wechsler Gedachtnistest—Revidierte Fassung, 2nd ed. Berne, Switzerland: Verlag Hans Huber; 2004.
  • 38
    Tewes U.HAWIE-R. Hamburg-Wechsler Intelligenztest fur Erwachsene, Revision 1991, 2nd ed. Berne, Switzerland: Verlag Hans Huber; 1994.
  • 39
    Brickenkamp R.Test d2. Aufmerksamkeits-Belastungs-Test, 9th ed. Gottingen, Germany: Hogrefe Verlag; 2002.
  • 40
    Reitan RM. Trail Making Test, 2nd ed. Tucson, Ariz: Reitan Neuropsychology Laboratory; 1992.
  • 41
    Aschenbrenner S,Tucha O,Lange KW.RWT. Regensburger Wortflussigkeits-Test. Gottingen, Germany: Hogrefe-Verlag; 2000.
  • 42
    Herrmann C,Buss U,Snaith RP.HADS-D. Hospital Anxiety and Depression Scale-German Version. Berne, Switzerland: Verlag Hans Huber; 1995.
  • 43
    Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Balingen, Germany: Spitta Verlag; 1999.
  • 44
    Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19: 203214.
  • 45
    Lezak MD,Howieson DB,Loring DW. Neuropsychological Assessment, 4th ed. New York, NY: Oxford University Press; 2004.
  • 46
    Shilling V,Jenkins V,Fallowfield L,Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003; 86: 405412.
  • 47
    Matthews KA,Kuller LH,Wing RR,Meilahn EN,Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996; 143: 971978.
  • 48
    Petitti DB,Buckwalter JG,Crooks VC,Chiu V. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol A Biol Sci Med Sci. 2002; 57: M532M538.